The Food and Drug Administration (FDA) has approved Kisqali, a breast cancer drug designed to treat advanced metastatic cases, for use in patients with earlier stage breast cancer. Novartis, the drug’s manufacturer, said that up to tens of thousands of women with early-stage breast cancer may get a new option that can help prevent their cancer